SCROLL DOWN

Better Therapy Brighter Outlook
LT3001

tPA is the only drug approved to treat stroke with serious side effects and unsatisfactory outcomes.

  • <3hr is eligible to receive tPA

  • Actual usage of tPA 3%~5%

  • High risk of hemorrhage

LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke.

NEWS

Investors

Learn More